Use of anti-CD40 ligand monoclonal antibody as antirejection therapy in a murine peripheral nerve allograft model

Microsurgery. 2004;24(4):309-15. doi: 10.1002/micr.20028.

Abstract

Monoclonal antibody directed against CD40 ligand prevents acute allograft rejection in several models of solid-organ transplantation. This study describes the use of CD40 ligand as antirejection therapy in a mouse peripheral nerve allograft model. C3H mice received 8-mm nerve isografts (n = 2) or nerve allografts from C57BL donors. Treated animals (n = 11) received anti-CD40 ligand antibody applied to the graft and by intraperitoneal injections postoperatively. At 3 weeks, nerve histology from treated animals was comparable to isografts, whereas untreated allografts demonstrated virtually no signs of regeneration. Walking-track analysis demonstrated a trend toward improved functional recovery in treated animals. In conclusion, blockade of the CD40 pathway suppresses nerve allograft rejection in mice, and facilitates regeneration comparable to isografts.

Publication types

  • Evaluation Study
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Antibodies, Monoclonal / immunology
  • Antibodies, Monoclonal / therapeutic use*
  • CD40 Ligand / immunology
  • CD40 Ligand / therapeutic use*
  • Graft Rejection / etiology
  • Graft Rejection / immunology
  • Graft Rejection / prevention & control*
  • Immunosuppression Therapy / methods
  • Male
  • Mice
  • Mice, Inbred C3H
  • Mice, Inbred C57BL
  • Models, Animal
  • Peripheral Nerves / transplantation*
  • Recovery of Function
  • Tissue Transplantation / adverse effects*
  • Transplantation, Homologous

Substances

  • Antibodies, Monoclonal
  • CD40 Ligand